Skip to main content
. 2020 May 26;100(9):1140–1157. doi: 10.1038/s41374-020-0441-4

Fig. 6. The expression of CCL3 and CCR5 in the human ESCC tissue samples.

Fig. 6

a Representative CCL3 immunoreactivities in human ESCC tissues. The immunoreactivity in the tumor nests was assessed and divided into low (n = 20) and high (n = 48) groups based on the staining intensity. Typical images are shown: low expression (i, iii) and high expression (ii, iv). Areas delimited by squares in (i) and (ii) (magnification: ×100; scale bar: 100 µm) are showed in higher magnification in (iii) and (iv) (magnification: ×400; scale bar: 20 µm), respectively. b Representative CCR5 immunoreactivities in human ESCC tissues. Immunoreactivity in the tumor nest was assessed and divided into low (n = 25) and high (n = 43) groups based on the staining intensity. Typical images are shown: low expression (i, iii) and high expression (ii, iv). Areas delimited by squares in (i) and (ii) (magnification: ×100; scale bar: 100 µm) are showed in higher magnification in (iii) and (iv) (magnification: ×400; Scale bar: 20 µm), respectively. c Double immunofluorescence was performed using antibodies against CCL3 (green) and CD204 (red). CCL3 was expressed in both cancer cells and CD204+ TAMs. Nuclei were stained by DAPI (blue). White dotted line indicates the edge of the tumor nest. Magnification: ×400. Scale bar: 10 µm.